文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于影像学的生物标志物可预测特发性脉络膜新生血管对抗血管内皮生长因子治疗的反应。

Imaging-based Biomarkers as Predictors of Response to Anti-VEGF Therapy in Idiopathic Choroidal Neovascularization.

机构信息

Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institutes of Medical Sciences, New Delhi, India.

出版信息

Middle East Afr J Ophthalmol. 2024 Jun 14;30(2):63-67. doi: 10.4103/meajo.meajo_173_21. eCollection 2023 Apr-Jun.


DOI:10.4103/meajo.meajo_173_21
PMID:39006934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11238929/
Abstract

PURPOSE: The purpose of this study was to identify biomarkers that predict the response of treatment-naive idiopathic choroidal neovascularization (iCNV) to anti-VEGF treatment. METHODS: Fourteen eyes diagnosed with iCNV underwent a dilated fundus examination, Swept Source Optical Coherence Tomography (SS-OCT) and Optical Coherence Tomography - Angiography (OCT-A), and were given an anti-VEGF injection. The same examinations were repeated at every follow-up visit. Analysis of the pre- and posttreatment images was done to identify possible biomarkers which were evaluated to check association with decreased need for multiple anti-VEGF injections. RESULTS: At presentation, 11 patients showed a compact pattern, while three patients showed an arborizing pattern on OCT angiography (P = 1). On follow-up imaging, seven patients showed a marked response, five patients showed a moderate response, and two patients showed a mild response to anti-VEGF injection. Among the seven patients showing a marked response, only one required a repeat injection (P = 0.03). On analysis of SS-OCT, a novel Retinal Pigment Epithelium (RPE) healing response was observed in posttreatment imaging of six patients (P = 0.59). CONCLUSION: A "marked" response to the first anti-VEGF injection results in a more sustained response and is a positive prognostic factor. RPE healing response is an interesting observation that merits further evaluation. Morphology of neovascular membranes has no effect on long-term need for multiple anti-VEGF injections.

摘要

目的:本研究旨在确定可预测未经治疗的特发性脉络膜新生血管(iCNV)对抗 VEGF 治疗反应的生物标志物。

方法:14 只诊断为 iCNV 的眼睛接受了散瞳眼底检查、扫频源光学相干断层扫描(SS-OCT)和光相干断层扫描血管造影(OCT-A),并接受了抗 VEGF 注射。每次随访时都会重复进行相同的检查。分析治疗前后的图像以识别可能的生物标志物,并评估其与减少对多次抗 VEGF 注射的需求的关联。

结果:在就诊时,11 名患者在 OCT 血管造影上显示出致密模式,而 3 名患者显示出分支模式(P = 1)。在随访成像上,7 名患者对抗 VEGF 注射有明显反应,5 名患者有中度反应,2 名患者有轻度反应。在显示明显反应的 7 名患者中,仅 1 名需要重复注射(P = 0.03)。在 SS-OCT 分析中,6 名患者在治疗后成像中观察到新的视网膜色素上皮(RPE)愈合反应(P = 0.59)。

结论:首次抗 VEGF 注射的“明显”反应可导致更持久的反应,是一个积极的预后因素。RPE 愈合反应是一个有趣的观察结果,值得进一步评估。新生血管膜的形态对多次抗 VEGF 注射的长期需求没有影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5f/11238929/0e5135873867/MEAJO-30-63-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5f/11238929/ec9d5b606c83/MEAJO-30-63-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5f/11238929/0e5135873867/MEAJO-30-63-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5f/11238929/ec9d5b606c83/MEAJO-30-63-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5f/11238929/0e5135873867/MEAJO-30-63-g002.jpg

相似文献

[1]
Imaging-based Biomarkers as Predictors of Response to Anti-VEGF Therapy in Idiopathic Choroidal Neovascularization.

Middle East Afr J Ophthalmol. 2023

[2]
Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization.

BMC Ophthalmol. 2020-3-19

[3]
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.

Retina. 2017-10

[4]
Anti-VEGF Treatment for Secondary Neovascularization in Pseudoxanthoma Elasticum - Age of Onset, Treatment Frequency, and Visual Outcome.

Am J Ophthalmol. 2024-9

[5]
SPATIAL PATTERN OF RETINAL PIGMENT EPITHELIUM TEAR DEVELOPMENT AND PROGRESSION AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Retin Cases Brief Rep. 2024-5-1

[6]
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.

Acta Ophthalmol. 2022-2

[7]
OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.

Retina. 2020-5

[8]
One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation.

Br J Ophthalmol. 2019-8-10

[9]
Anatomical and visual outcomes of ranibizumab injections in retinal pigment epithelium tears.

Arq Bras Oftalmol. 2015

[10]
Choroidal neovascularization due to choroidal osteoma treated with anti-vascular endothelial growth factor therapy: An optical coherence tomography angiography study.

Eur J Ophthalmol. 2019-5

本文引用的文献

[1]
Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization.

BMC Ophthalmol. 2020-3-19

[2]
Long-Term Efficacy of Intravitreal Conbercept Injection in the Treatment of Idiopathic Choroidal Neovascularization.

J Ocul Pharmacol Ther. 2020-3

[3]
Genetic factors for idiopathic choroidal neovascularization.

Ophthalmic Genet. 2019-8

[4]
Treatment of idiopathic choroidal neovascular membrane with ranibizumab - our experience.

Cesk Slov Oftalmol. 2019

[5]
OPTICAL COHERENCE TOMOGRAPHY, FLUORESCEIN ANGIOGRAPHY, AND DIAGNOSIS OF CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION.

Retina. 2019-9

[6]
Characterization of Idiopathic Choroidal Neovascularization Using Fluorescein Angiography, Indocyanine Green Angiography, and Optical Coherence Tomography Angiography.

Ophthalmic Surg Lasers Imaging Retina. 2018-7-1

[7]
Characteristics of type 1 and 2 CNV in exudative AMD in OCT-Angiography.

Graefes Arch Clin Exp Ophthalmol. 2017-5

[8]
Long-Term Outcome and Recurrence of Idiopathic Choroidal Neovascularization Treated with Intravitreal Bevacizumab.

J Ocul Pharmacol Ther. 2016-9

[9]
The Application of OCTA in Assessment of Anti-VEGF Therapy for Idiopathic Choroidal Neovascularization.

J Ophthalmol. 2016

[10]
Ranibizumab versus bevacizumab for the treatment of idiopathic choroidal neovascularization: 2-Year results.

Eur J Ophthalmol. 2016

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索